Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2020-09-25 M&A Activity
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
수시공시의무관련사항(공정공시)
M&A Activity Classification · 100% confidence The document is a regulatory disclosure (Fair Disclosure) regarding the planned merger of Celltrion, Celltrion Healthcare, and Celltrion Pharm, as well as the establishment of a holding company. This type of corporate announcement regarding M&A activity and structural changes falls under the 'M&A Activity' category. It is not a report publication announcement (RPA) as it provides the substantive details of the corporate action rather than just announcing the availability of a report.
2020-09-25 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Major Shareholding Notification Classification · 100% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Celltrion Pharm. This type of filing is a mandatory regulatory disclosure in South Korea regarding the status of large business groups, including shareholding structures, inter-company transactions, and financial guarantees. Since it does not fit into specific categories like 10-K, Earnings Release, or Proxy Statements, and is a standard regulatory requirement for corporate groups, it falls under the 'Regulatory Filings' (RNS) category.
2020-08-27 Korean
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Celltrion Pharm, covering the period from January 1, 2020, to June 30, 2020. It contains detailed financial statements, business operations, management discussions, and governance information. As it is a comprehensive financial report for a period shorter than a full fiscal year (a half-year report) and contains substantive financial data, it is classified as an Interim/Quarterly Report. H1 2020
2020-08-14 Korean
조회공시요구(풍문또는보도)에대한답변(미확정)
M&A Activity Classification · 100% confidence The document is a regulatory response to a stock exchange inquiry regarding rumors of a merger between Celltrion and Celltrion Healthcare. It is a formal disclosure of 'undetermined' status regarding corporate activity (merger). Since it is a regulatory filing regarding corporate rumors and does not fit into specific categories like M&A (which would be a definitive agreement) or other specialized reports, it falls under the general regulatory filing category.
2020-08-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a standard Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a mandatory disclosure filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) when an executive or major shareholder changes their shareholding position. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers insider transactions and changes in ownership by company directors and executives.
2020-08-05 Korean
[기재정정]특수관계인으로부터받은담보
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Celltrion Pharm regarding a correction (정정신고) to a previous disclosure about collateral received from a related party. It details specific financial transaction data, board approval dates, and collateral terms. Since it is a formal regulatory disclosure of a corporate transaction that does not fit into specific categories like dividends, M&A, or share buybacks, it falls under the general regulatory filing category.
2020-06-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.